LYON, France, March 23, 2023 – POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases , announces today that it has finalized (1) agreements with its creditors to restructure its existing debt and (2) the establishment of a new equity financing line with IRIS comprising a first drawdown of 3.5 million euros. Thanks to these agreements, and including the full drawing down of the new equity financing line, the Company extends its financial visibility and believes that its resources will be sufficient to finance its operations and its investment needs until the end of the 2nd quarter of 2025.
To receive information from POXEL in real time, send a request to [email protected].